CGON
CG Oncology, Inc. Common stock NASDAQ Listed Jan 25, 2024$71.40
Mkt Cap $6.3B
52w Low $23.65
89.5% of range
52w High $77.00
50d MA $66.11
200d MA $56.92
P/E (TTM)
—
EV/EBITDA
—
P/B
7.3x
Debt/Equity
0.0x
ROE
-21.4%
P/FCF
-41.7x
RSI (14)
47.60
ATR (14)
$3.73
Beta
0.70
50d MA
$66.11
200d MA
$56.92
Avg Volume
1.1M
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
400 Spectrum Center Drive · Irvine, DE 75247 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 69.18 | -0.4% | +0.6% | -0.4% | +4.0% | +2.7% | -6.0% | — |
| May 7, 2026 | BMO | — | — | — | 68.01 | +0.2% | +1.7% | +0.6% | -0.4% | +4.0% | +2.7% | — |
| Feb 27, 2026 | AMC | -0.61 | -0.51 | +16.4% | 58.80 | -2.9% | -1.8% | +4.8% | +1.7% | -1.9% | +2.5% | — |
| Nov 14, 2025 | AMC | -0.56 | -0.57 | -2.0% | 41.01 | +1.0% | +0.6% | +3.2% | +0.1% | -4.4% | +4.2% | — |
| Aug 8, 2025 | AMC | -0.49 | -0.54 | -10.2% | 24.85 | -0.4% | -3.6% | +4.2% | +6.2% | -2.0% | -1.0% | — |
| May 13, 2025 | AMC | -0.39 | -0.45 | -15.4% | 24.18 | -0.4% | -0.0% | +4.9% | +0.3% | -2.2% | +6.8% | — |
| Mar 28, 2025 | AMC | -0.41 | -0.48 | -17.1% | 26.42 | +1.5% | -7.3% | -10.0% | +0.9% | -15.7% | -8.2% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.28 | +33.3% | 33.24 | +1.1% | +1.2% | -2.2% | +1.9% | -0.8% | +3.5% | — |
| May 9, 2024 | AMC | -0.35 | -0.36 | -2.9% | 30.02 | -0.0% | -5.1% | -9.3% | +5.7% | +2.5% | +10.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Wolfe Research | Initiates | Peer Perform | — | $62.93 | $62.13 | -1.3% | +0.6% | +2.3% | -0.3% | -0.5% | -3.7% |
| Apr 27 | RBC Capital | Maintains | Outperform → Outperform | — | $68.68 | $69.10 | +0.6% | -2.7% | -1.9% | -1.2% | +3.1% | -0.7% |
| Apr 17 | JP Morgan | Maintains | Overweight → Overweight | — | $66.34 | $67.61 | +1.9% | +10.7% | -4.1% | +2.0% | -2.7% | +0.0% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.55 | $68.56 | +1.5% | +3.3% | -1.3% | -0.5% | -1.3% | +0.0% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.11 | $55.79 | -0.6% | +4.8% | -1.8% | +4.8% | +1.7% | -1.9% |
| Feb 10 | Truist | Maintains | Buy → Buy | — | $51.08 | $51.37 | +0.6% | +3.9% | +0.9% | -3.6% | -0.2% | +4.6% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $54.69 | $55.03 | +0.6% | +4.5% | -2.2% | -3.7% | -0.9% | +3.4% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $53.07 | $53.20 | +0.2% | +3.1% | -0.1% | +4.5% | -2.2% | -3.7% |
| Jan 12 | Truist | Maintains | Buy → Buy | — | $54.20 | $55.31 | +2.0% | -0.9% | -2.1% | +5.6% | -4.4% | +3.1% |
| Nov 17 | RBC Capital | Maintains | Outperform → Outperform | — | $41.01 | $41.43 | +1.0% | +0.6% | +3.2% | +0.1% | -4.4% | +4.2% |
| Sep 26 | JP Morgan | Maintains | Overweight → Overweight | — | $36.48 | $37.46 | +2.7% | +2.9% | +4.1% | +3.1% | -2.0% | +1.0% |
| Sep 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.76 | $36.48 | +2.0% | +5.5% | +2.9% | -4.9% | +0.4% | -0.9% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.34 | $35.10 | +5.3% | +3.8% | +3.4% | +5.5% | +2.9% | -4.9% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $33.07 | $33.81 | +2.2% | +1.9% | -0.7% | +0.5% | -1.4% | +0.5% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.07 | $33.81 | +2.2% | +1.9% | -0.7% | +0.5% | -1.4% | +0.5% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.94 | $31.13 | +0.6% | +6.9% | +1.9% | -0.7% | +0.5% | -1.4% |
| Jul 16 | RBC Capital | Maintains | Outperform → Outperform | — | $24.95 | $24.70 | -1.0% | +4.5% | +9.1% | -6.0% | +0.6% | -3.3% |
| Jun 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.46 | $25.67 | +0.8% | +3.1% | +0.2% | -2.8% | +0.4% | +0.5% |
| May 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.43 | $24.48 | -3.7% | -2.2% | +6.8% | -1.3% | -1.8% | -1.2% |
| Apr 29 | RBC Capital | Maintains | Outperform → Outperform | — | $27.97 | $28.26 | +1.0% | -3.7% | +0.0% | +3.0% | +4.7% | -3.0% |
| Apr 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.37 | $31.00 | +38.6% | +25.0% | -3.7% | +0.0% | +3.0% | +4.7% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.37 | $31.00 | +38.6% | +25.0% | -3.7% | +0.0% | +3.0% | +4.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.42 | $26.82 | +1.5% | -7.3% | -10.0% | +0.9% | -15.7% | -8.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.53 | $28.41 | -0.4% | -3.5% | -3.6% | +1.5% | -1.9% | -7.3% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.20 | $29.66 | -1.8% | -5.0% | -2.5% | +5.9% | -1.7% | -0.1% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.46 | $30.00 | -1.5% | -0.9% | -5.0% | -2.5% | +5.9% | -1.7% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.56 | $33.86 | +0.9% | +3.1% | -3.9% | +1.4% | -5.8% | -9.0% |
| Dec 6 | RBC Capital | Maintains | Outperform → Outperform | — | $33.56 | $33.86 | +0.9% | +3.1% | -3.9% | +1.4% | -5.8% | -9.0% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.98 | $37.45 | +1.3% | -4.9% | +1.0% | -7.3% | +0.9% | -1.2% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.69 | $39.68 | -0.0% | -6.8% | -4.9% | +1.0% | -7.3% | +0.9% |
| Oct 8 | BofA Securities | Maintains | Buy → Buy | — | $35.48 | $35.42 | -0.2% | -1.9% | -0.3% | -0.7% | +4.7% | +4.0% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.00 | $37.01 | +0.0% | +2.0% | -1.8% | +5.5% | -0.3% | -1.7% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.71 | $32.99 | +0.9% | -0.9% | -0.1% | +5.8% | -5.0% | +10.6% |
| May 14 | Goldman Sachs | Upgrade | Neutral → Buy | — | $25.84 | $27.80 | +7.6% | +5.7% | +2.5% | +10.6% | -3.2% | -0.8% |
| May 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $28.50 | $29.00 | +1.8% | -9.3% | +5.7% | +2.5% | +10.6% | -3.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.02 | $30.01 | -0.0% | -5.1% | -9.3% | +5.7% | +2.5% | +10.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.27 | $37.01 | +2.0% | -3.2% | -3.3% | -4.5% | -7.4% | -5.1% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.27 | $37.01 | +2.0% | -3.2% | -3.3% | -4.5% | -7.4% | -5.1% |
| May 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $40.62 | $41.16 | +1.3% | -2.8% | -8.2% | -3.2% | -3.3% | -4.5% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.39 | $38.65 | +0.7% | -1.7% | +1.9% | +1.8% | -0.3% | -1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | POST LEONARD E | — | Sell | 1,000 | $71.17 | $71K | — | -2.31% | -2.53% |
| Jul 10, 2026 | Mulay James | — | Sell | 24,165 | $75.16 | $1.8M | — | +1.71% | +2.18% |
| Jun 25, 2026 | Liu Brian Guan-Chyun | — | Buy | 371,085 | $66.87 | $24.8M | 1,886,236 | -3.63% | -0.09% |
| Jun 24, 2026 | POST LEONARD E | — | Sell | 5,000 | $70.00 | $350K | — | -1.21% | -0.75% |
| Jun 22, 2026 | POST LEONARD E | — | Sell | 5,000 | $65.00 | $325K | — | +4.55% | -3.63% |
| Jun 15, 2026 | Mulay James | — | Sell | 1,310 | $60.12 | $79K | — | +0.25% | +4.55% |
| Jun 15, 2026 | Mulay James | — | Sell | 654 | $60.12 | $39K | — | +0.25% | +4.55% |
| Jun 4, 2026 | POST LEONARD E | — | Sell | 1,000 | $54.50 | $54K | — | +1.27% | +3.33% |
8-K · 5.02
!!! Very High
CG Oncology, Inc. -- 8-K 5.02: Executive Change
May 26
8-K · 2.02
!! High
CG Oncology, Inc. -- 8-K 2.02: Earnings Results
CG Oncology reported Q1 2026 financial results, providing investors with updated operational performance and financial metrics to assess the company's progress and cash position.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at CGON is receiving $520,000 base salary plus 45% bonus potential, with equity grants vesting April 2026, signaling leadership continuity and standard compensation that shouldn't materially impact valuation.
Apr 13
8-K
CG Oncology, Inc. -- 8-K Filing
CG Oncology anticipates releasing interim data from its Phase III PIVOT-006 trial evaluating cretostimide for non-muscle invasive bladder cancer, a potential catalyst for investors monitoring the company's clinical pipeline progress.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 6,984,808 | $473M | Added | Mar 2026 |
| 2 | Decheng Capital Llc | 6,371,669 | $431M | — | Mar 2026 |
| 3 | Fmr Llc | 3,764,844 | $255M | Reduced | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 3,095,098 | $209M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 3,033,625 | $205M | New | Mar 2026 |
| 6 | Franklin Resources Inc | 1,507,005 | $102M | Reduced | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 1,449,364 | $98M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 1,311,978 | $89M | Reduced | Mar 2026 |
| 9 | Avidity Partners Management Lp | 1,288,948 | $87M | New | Mar 2026 |
| 10 | Braidwell Lp | 1,870,571 | $78M | Reduced | Dec 2025 |
| 11 | Clearbridge Investments, Llc | 730,283 | $49M | Added | Mar 2026 |
| 12 | Farallon Capital Management Llc | 674,000 | $46M | New | Mar 2026 |
| 13 | Morgan Stanley | 1,090,038 | $45M | Reduced | Dec 2025 |
| 14 | Foresite Capital Management V, Llc | 1,004,050 | $42M | — | Dec 2025 |
| 15 | Jpmorgan Chase & Co | 559,586 | $36M | Reduced | Mar 2026 |
| 16 | Northern Trust Corp | 519,669 | $35M | Added | Mar 2026 |
| 17 | Woodline Partners Lp | 492,891 | $33M | — | Mar 2026 |
| 18 | Candriam S.c.a. | 797,615 | $33M | Reduced | Dec 2025 |
| 19 | Ensign Peak Advisors, Inc | 456,012 | $31M | Reduced | Mar 2026 |
| 20 | Point72 Asset Management | 399,392 | $27M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$6.30B
Enterprise Value
$4.78B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.42x
P/B
7.33x
P/S
1241.90x
P/FCF
-41.66x
EV/EBITDA
—
Shares Out
77.3M
Financials (TTM)
Revenue
$5.1M
Net Income
-$186.7M
EBITDA
-$184.5M
Free Cash Flow
-$132.5M
Op Cash Flow
-$132.3M
EPS Basic
$-2.08
EPS Diluted
$-2.34
EPS Forward
$-2.40
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$791.6M
Total Liab.
$39.0M
Total Equity
$752.6M
Cash
$742.2M
LT Debt
$6.1M
Book Value/Sh
$9.74
Debt/Equity
0.01x
Current Ratio
24.63
Quick Ratio
24.58
Returns & Growth
ROE
-21.4%
ROA
-20.3%
ROIC
-25.1%
Rev Growth YoY
+254.7%
EPS Growth YoY
-47.5%
Price Returns
2W
-0.4%
1M
+3.1%
3M
+6.3%
6M
+45.1%
12M
+165.0%
Technicals
52W High
$77.00
52W Low
$23.65
50d MA
$66.11
200d MA
$56.92
RSI (14)
47.60
ATR (14)
$3.73
Beta
0.70
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$79.86
High
$93.00
Low
$70.00
Median
$79.00
Data updated apr 25, 2026 1:01am
· Source: financialmodelingprep.com